Tech Company Financing Transactions
Shennon Biotechnologies Funding Round
Shennon Biotechnologies, operating out of San Francisco, secured $13 million in funding from DCVC, AV8 Ventures and Foundation Capital.
Transaction Overview
Company Name
Announced On
3/13/2023
Transaction Type
Venture Equity
Amount
$13,000,000
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to further expand the capabilities of the platform and scale discovery efforts to build a pipeline of effective targets for solid tumors.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2325 3rd St 298
San Francisco, CA 94107
USA
San Francisco, CA 94107
USA
Phone
Undisclosed
Website
Email Address
Overview
We analyze, understand, and manipulate massive numbers of cells on the single cell level to develop more effective treatments for human diseases. Our proprietary ultra-high throughput single cell platform enables us to functionally profile millions of immune cells on the single cell level at the same time, pulling out rare and difficult-to-find targets that are like the needles in a haystack. This allows us to create immunotherapies that are more targeted and more effective. We are using this unique platform to first develop cell therapies for solid tumors.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Li Sun
Chief Technical Officer
Kaveh Milaninia
Browse more venture capital transactions:
Prev: 3/13/2023: Carbonomy venture capital transaction
Next: 3/13/2023: Green Li-ion venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to report on all VC transactions involving tech companies. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs